Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dacogen decitabine: Phase II

In a U.S. Phase II trial, 43% (55/130) of patients achieved an objective response as defined

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE